Bi -institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer

被引：0
|
作者：
Soni, Y. S. [1 ]
Lock, D. [2 ]
Ballas, L. K. [3 ]
Hwang, L. [2 ]
Cole, S. [4 ]
D'Souza, A. [5 ]
Zhang, T. [4 ]
Garant, A. [1 ]
Yang, D. X. [1 ]
Arafat, W. [4 ]
Desai, N. B. [1 ]
机构：
[1] Univ Texas Southwestern Med Ctr, Dept Radiat Oncol, Dallas, TX USA
[2] LAC USC Med Ctr, Dept Radiat Oncol, Los Angeles, CA USA
[3] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA USA
[4] Univ Texas Southwestern Med Ctr, Dept Hematol & Oncol, Dallas, TX USA
[5] LAC USC Med Ctr, Dept Hematol & Oncol, Los Angeles, CA USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
222
引用
收藏
页码：S74 / S75
页数：2
相关论文
共 50 条
  • [31] Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
    Kirollos S. Hanna
    Drugs, 2020, 80 : 1 - 7
  • [32] FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
    Chang, Elaine
    Weinstock, Chana
    Zhang, Lijun
    Charlab, Rosane
    Dorff, Sarah E.
    Gong, Yutao
    Hsu, Vicky
    Li, Fang
    Ricks, Tiffany K.
    Song, Pengfei
    Tang, Shenghui
    Waldron, Peter E.
    Yu, Jingyu
    Zahalka, Eias
    Goldberg, Kirsten B.
    Pazdur, Richard
    Theoret, Marc R.
    Ibrahim, Amna
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 922 - 927
  • [33] Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma.
    Teo, Min Yuen
    Ratna, Neha
    Regazzi, Ashley Marie
    Zimmerman, Danielle Elise
    McHugh, Deaglan Joseph
    Laccetti, Andrew Leonard
    Xiao Han
    Lee, Chung-Han
    Aggen, David Henry
    Funt, Samuel Aaron
    Bajorin, Dean F.
    Iyer, Gopa
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [34] Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma
    Minato, Akinori
    Takaba, Tomohisa
    Sugita, Yoshihiro
    Kaneko, Yuya
    Hongyo, Ryota
    Tanaka, Toshinobu
    Bando, Taro
    Sugi, Takaomi
    Mizushima, Yui
    Matsukawa, Takuo
    Jojima, Kazumasa
    Higashijima, Katsuyoshi
    Nagata, Yujiro
    Tomisaki, Ikko
    Kashiwagi, Eiji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [35] Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.
    Jindy, Tanya
    Jiang, Cindy Y.
    Alhalabi, Omar
    Nguyen, Charles B.
    Nizam, Amanda
    Basu, Arnab
    Bilen, Mehmet Asim
    Zakharia, Yousef
    Milowsky, Matthew I.
    Brown, Jason R.
    Kilari, Deepak
    Emamekhoo, Hamid
    Hoimes, Christopher J.
    Khaki, Ali Raza
    Gupta, Shilpa
    Grivas, Petros
    Bellmunt, Joaquim
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 652 - 652
  • [36] Incidence and risk of peripheral sensory neuropathy with enfortumab vedotin in patients with advanced urothelial cancer: A systematic review and meta-analysis
    Shah, Yousuf
    Sher, Amna Falak
    Wu, Shenhong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Retrospective analysis of urothelial carcinoma treated with enfortumab vedotin at our institution
    Imai, Toru
    Kita, Shosuke
    Shimoi, Tatsunori
    Yazaki, Shu
    Tokura, Momoko
    Kawachi, Asuka
    Okuma, Hitomi S.
    Nakamura, Eijiro
    Arakaki, Motoko
    Saito, Ayumi
    Yamamoto, Kasumi
    Maejima, Aiko
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Noguchi, Emi
    Matsui, Yoshiyuki
    Fujiwara, Yasuhiro
    Yonemori, Kan
    ANNALS OF ONCOLOGY, 2023, 34 : S1417 - S1417
  • [38] Managing potential adverse events during treatment with enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer
    Brower, Blaine
    Mccoy, Asia
    Ahmad, Hiba
    Eitman, Cheryl
    Bowman, I. Alex
    Rembisz, Jennifer
    Milowsky, Matthew I.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [39] Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.
    Zschaebitz, Stefanie
    Kluemper, Niklas
    Holzwarth, Nina
    Biernath, Nadine
    Hoellein, Alexander
    Niegisch, Guenter
    Seidl, Daniel
    Aydogdu, Can
    Handke, Analena
    Paffenholz, Pia
    Schlack, Katrin
    Cathomas, Richard
    Erne, Eva
    Banek, Severine
    Tauber, Robert
    Casuscelli, Jozefina
    Seitz, Anna Katharina
    Gruenwald, Viktor
    Darr, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 553 - 553
  • [40] Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status
    Furubayashi, Nobuki
    Minato, Akinori
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Haraguchi, Yusuke
    Koga, Toshiki
    Song, Yoohyun
    Harada, Kenichi
    Kuroiwa, Kentaro
    Seki, Narihito
    Fujimoto, Naohiro
    Nakamura, Motonobu
    ANTICANCER RESEARCH, 2024, 44 (08) : 3409 - 3417
12345